Answer
Fainting (syncope) is a common adverse reaction with mavacamten (affecting at least 1 in 100 but fewer than 1 in 10 patients), reported in 5% of patients in phase 3 studies.
Sources for this answer
- Mavacamten BMS 2.5 mg, 5 mg, 10 mg, 15 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.8 Undesirable effects · Version 6Document updated
Sources checked